Table 2.
Age and frequency of individuals with at least one gastrointestinal therapeutic drug reimbursed, in combination with another therapeutic class in 2016.
| Gastrointestinal therapeutic drug
classes |
A02A |
A02BC |
A02BX |
A02X |
A03 |
A04 |
A06 |
A07 |
|---|---|---|---|---|---|---|---|---|
| n (million) | 0.9 |
13.9 |
2.6 |
3.3 |
11.5 |
4.1 |
5.9 |
5.8 |
| % | % | % | % | % | % | % | % | |
| Median age (year) | 61 | 65 | 59 | 43 | 47 | 34 | 68 | 42 |
| Interquartile range (Q1–Q3) | 46–72 | 52–76 | 41–72 | 20–64 | 26–66 | 13–58 | 51–81 | 16–62 |
| Gastrointestinal therapeutic drug classes | ||||||||
| Alone | 9.2 | 44.9 | 11.8 | 10.4 | 23.0 | 11.1 | 26.0 | 15.0 |
| With one other class | ||||||||
| A02A | – | 1.0 | 0.2 | 0.1 | 0.4 | 0.1 | 0.3 | 0.1 |
| A02BC | 15.7 | – | 22.1 | 3.8 | 10.9 | 3.4 | 18.0 | 4.7 |
| A02BX | 0.5 | 4.1 | – | 0.4 | 1.0 | 0.3 | 0.7 | 0.5 |
| A02X | 0.4 | 0.9 | 0.6 | – | 3.2 | 2.7 | 0.5 | 2.9 |
| A03 | 5.0 | 9.1 | 4.5 | 11.4 | – | 9.6 | 11.0 | 15.2 |
| A04 | 0.5 | 1.0 | 0.5 | 3.5 | 3.5 | – | 0.7 | 6.0 |
| A06 | 1.8 | 7.6 | 1.7 | 1.0 | 5.6 | 1.0 | – | 1.3 |
| A07 | 0.7 | 2.0 | 1.0 | 5.1 | 7.6 | 8.4 | 1.3 | – |
| All the pairs | 24.7 | 25.9 | 30.6 | 25.4 | 32.4 | 25.6 | 32.7 | 30.8 |
| With two other classes | ||||||||
| A02A and one other class | – | 1.2 | 0.2 | 0.4 | 1.0 | 0.3 | 0.9 | 0.3 |
| A02BC–A03 | 9.6 | – | 1.9 | 4.5 | – | 3.7 | 10.2 | 5.0 |
| A02BC–A06 | 4.1 | – | 1.0 | 0.9 | 5.2 | 1.0 | – | 1.0 |
| A02BC and one other class | 5.0 | 0.0 | 0.7 | 3.6 | 7.4 | 2.7 | 4.5 | 3.0 |
| A02BX–A03 | 0.4 | 1.9 | – | 0.5 | – | 0.4 | 0.6 | 0.5 |
| A02BX and one other class | 0.1 | 1.7 | 0.0 | 0.4 | 0.7 | 0.3 | 0.1 | 0.3 |
| A02X–A03 | 0.6 | 1.0 | 0.1 | – | – | 5.1 | 0.8 | 4.4 |
| A02X–A07 | 0.2 | 0.5 | 0.0 | – | 2.2 | 2.1 | 0.3 | |
| A02X and one other class | 0.2 | 0.4 | 0.0 | 0.0 | 2.2 | 0.2 | 0.1 | 1.8 |
| A03–A04 | 0.7 | 1.1 | 0.1 | 6.5 | – | – | 1.2 | 10.3 |
| A03–A06 | 2.3 | 4.3 | 0.3 | 1.5 | – | 1.7 | – | 1.7 |
| A03–A07 | 1.0 | 2.1 | 0.2 | 7.9 | – | 14.4 | 1.7 | – |
| A04–A06 | 0.1 | 0.3 | 0.0 | 0.2 | 0.6 | – | – | 0.4 |
| A04–A07 | 0.2 | 0.4 | 0.1 | 2.7 | 5.2 | – | 0.4 | – |
| A06–A07 | 0.1 | 0.4 | 0.0 | 0.5 | 0.8 | 0.5 | – | – |
| All the triplets | 25.3 | 15.7 | 25.4 | 29.7 | 26.0 | 32.7 | 21.5 | 28.9 |
| With three or more other classes | 40.8 | 13.4 | 32.4 | 34.5 | 18.6 | 30.6 | 19.8 | 25.4 |
| Total | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| Other therapeutic classes | ||||||||
| Vitamin K antagonists (B01AA) | 2.4 | 3.2 | 2.4 | 2.1 | 1.6 | 1.2 | 4.5 | 1.7 |
| Heparin (B01AB) | 5.2 | 6.5 | 5.4 | 4.3 | 4.7 | 4.2 | 7.9 | 3.6 |
| Platelet-aggregation inhibitors (B01AC) | 13.0 | 16.3 | 12.2 | 8.3 | 7.2 | 5.2 | 17.4 | 7.0 |
| Thrombin inhibitors (B01AE) | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | 0.1 | 0.4 | 0.2 |
| Direct-factor-Xa inhibitors (B01AF) | 1.7 | 2.1 | 1.6 | 1.2 | 1.0 | 0.8 | 2.6 | 1.0 |
| Other antithrombotics (B01AX) | 0.7 | 0.7 | 0.6 | 0.5 | 0.5 | 0.4 | 0.7 | 0.4 |
| At least one platelet-aggregation inhibitor or antithrombotic | 20.2 | 25.1 | 19.5 | 14.1 | 13.1 | 10.1 | 28.0 | 11.8 |
| Nonsteroidal anti-inflammatory drugs | 53.3 | 61.5 | 49.3 | 49.3 | 51.0 | 51.5 | 43.7 | 48.7 |
| Corticosteroids | 33.6 | 32.2 | 32.8 | 32.5 | 30.7 | 35.1 | 29.7 | 34.1 |
A02A: antacids; A02BC: PPIs; A02BX: other drugs for peptic ulcer and gastro-oesophageal reflux disease; A02X: other drugs for acid-related disorders; A03: drugs for functional gastrointestinal disorders; A04: antiemetics and antinauseants, A06: drugs for constipation, A07: antidiarrhoeals, intestinal anti-inflammatory/anti-infective agents.
PPIs, proton-pump inhibitors.